Shantha to set up insulin manufacturing facility in Hyderabad

Shantha Biotechnics, a Sanofi company, will set up a Rs 460 crore insulin manufacturing facility here.
The laying of the foundation stone of the new facility will be done by Telangana Chief Minister K Chandrasekhar Rao, a company statement issued today said.
At the new facility, Insuman, a leading human insulin product from Sanofi's range of diabetes treatment will be manufactured.
Sanofi will make an investment of Rs 460 crore in the facility, it said.
Located in Muppireddipalli (Telangana), the facility will be equipped with the latest technology to produce Insuman. This will be Sanofi's second plant apart from its existing Insuman manufacturing plant in Frankfurt.

The construction of the 13,400 square-metre building will begin immediately, with the site fully operational by 2019, it said.

Shantha Biotechnics CEO Harish Iyer said, "For the first time, we will be able to manufacture insulin in cartridges here. This state-of-the-art facility will have the capability to ramp up manufacturing volumes to 60 million Insuman cartridges per year within two to three years of commercial manufacturing."
While Sanofi's Frankfurt facility will continue to manufacture the human insulin, Insuman, Shantha Biotechnics' new facility will contribute towards addressing local demand for Insuman, the statement said.
Managing Director - India and Vice President - South Asia, Sanofi, Shailesh Ayyangar said, "By setting up a manufacturing site at Shantha Biotechnics for our diabetes product- Insuman, Sanofi is a front runner in its endeavour of addressing the growing epidemic of diabetes in India.